Patent intelligence · US
US 11554140
Nucleic acid, chimeric antigen receptor expression plasmid, chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer
Nucleic acid, chimeric antigen receptor expression plasmid, chimeric antigen receptor expressing cell, use thereof, and pharmaceutical compo…
Patent details — US 11554140
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 17, 2023
- Expiration
- Jan 12, 2043
- Applicant
- China Medical University Hospital
- Claims
- 5
- CPC classes
- A61K, A61K2039/505, A61K2239/38, A61K2239/47
Quick answer
US 11554140 (Nucleic acid, chimeric antigen receptor expression plasmid, chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer) is held by China Medical University Hospital. Status: granted. Granted Jan 17, 2023. Expires Jan 12, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- China Medical University Hospital
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K2039/505, A61K2239/38, A61K2239/47, A61K2239/49, A61K2239/54
More from China Medical University Hospital
Related pharmaceutical patents in our USPTO index.
-
US 12427137
Method for reducing methane production in animal stomach
granted -
US 12421269
SGLT2/DPP4 inhibitor and application thereof
granted -
US 12403167
Phenylethanoid glycoside extract from Acanthus ilicifolius L., preparation method thereof and use as anti-liver injury medicament
granted -
US 12397034
Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons
granted -
US 12389931
Oyster peptide with effect of improving sexual function and preparation method thereof
granted -
US 12383535
Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor
granted -
US 12378241
Pyridine derivative as FGFR and VEGFR dual inhibitors
granted -
US 12371434
MLL1 inhibitors and anti-cancer agents
granted
Frequently asked questions
What is US patent 11554140?
US 11554140 (Nucleic acid, chimeric antigen receptor expression plasmid, chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer) is held by China Medical University Hospital. Status: granted. Granted Jan 17, 2023. Expires Jan 12, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11554140?
China Medical University Hospital is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 335 pharmaceutical patents for this assignee.
When does US 11554140 expire?
Our index shows an expiration date of Jan 12, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.